Renal Sympathetic-Nerve Ablation for Uncontrolled Hypertension

Evidence of the efficacy of bevacizumab in patients with HHT. Both cases also show that symptoms and transfusion requirements improve with this therapy, without an appreciable change in arteriovenous malformations. Like Oosting et al., we found no difference in the size of our patient's pulmonary arteriovenous malformations on CT before and after bevacizumab. Their experience demonstrates the long-term safety and tolerability of bevacizumab in such patients. Our patient continues to report symptomatic benefit more than a year after completing therapy, and he has required only one intravenous infusion of iron during this time. His hemoglobin levels have remained stable at 14 to 15 g per deciliter. The cost of…